CN1590550A - T carrier and its construction method - Google Patents
T carrier and its construction method Download PDFInfo
- Publication number
- CN1590550A CN1590550A CN 200410047905 CN200410047905A CN1590550A CN 1590550 A CN1590550 A CN 1590550A CN 200410047905 CN200410047905 CN 200410047905 CN 200410047905 A CN200410047905 A CN 200410047905A CN 1590550 A CN1590550 A CN 1590550A
- Authority
- CN
- China
- Prior art keywords
- carrier
- sequence
- restriction enzyme
- ahdi
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010276 construction Methods 0.000 title description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 101150066555 lacZ gene Proteins 0.000 claims abstract description 13
- 241000701867 Enterobacteria phage T7 Species 0.000 claims abstract description 3
- 241001515965 unidentified phage Species 0.000 claims abstract description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 46
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- 101150102092 ccdB gene Proteins 0.000 claims description 19
- 238000005520 cutting process Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000010367 cloning Methods 0.000 abstract description 24
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 44
- 238000003752 polymerase chain reaction Methods 0.000 description 40
- 239000013612 plasmid Substances 0.000 description 34
- 238000012408 PCR amplification Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 13
- 239000013598 vector Substances 0.000 description 12
- 238000000246 agarose gel electrophoresis Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000003292 glue Substances 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 108010042407 Endonucleases Proteins 0.000 description 7
- 102000004533 Endonucleases Human genes 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 7
- 108090000364 Ligases Proteins 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 101150092880 DREB1A gene Proteins 0.000 description 3
- 241000702371 Enterobacteria phage f1 Species 0.000 description 3
- 101150043797 NCED3 gene Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101800004637 Communis Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- KHWCHTKSEGGWEX-UHFFFAOYSA-N deoxyadenylic acid Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(O)=O)O1 KHWCHTKSEGGWEX-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 101100064126 Arabidopsis thaliana DREB1A gene Proteins 0.000 description 1
- 101100008047 Caenorhabditis elegans cut-3 gene Proteins 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 101710186981 DNA gyrase subunit A Proteins 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 101150043283 ccdA gene Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Images
Landscapes
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A T carrier with higher TA cloning efficiency includes the Amp gene sequence of pBlue Script II SK(-), the ColEI ori sequence of pBlue Script II SK (-), the flori sequence of pBlue Script II SK(-), the lacZ gene sequence of pBlue Script IISK (-), the T3 bacteriophage promoter sequence of pBlue Script II SK (-), T7 bacteriophage promoter sequence of pBlue Script II SK(-), and two polycloning site sequences at both ends. The process for preparing T carrier is also disclosed.
Description
Technical field
The present invention relates to a kind of carrier and construction process thereof in the genetically engineered field, particularly a kind of T carrier and construction process thereof.
Background technology
PCR (polymerase chain reaction) is the normal experiment technology in the molecular biology.Need in most cases pcr amplification product is cloned on the plasmid vector, so as to the PCR product check order, operation such as in-vitro transcription, external translation.The method of clone PCR products has a variety of, but method the most direct, most convenient is the TA clone.So-called TA clone has the PCR product cloning to 3 of single A tail with 3 ' end ' end has on the T carrier of single T tail.TA clone's theoretical foundation is: in the pcr amplification process, because it is active and terminally add single deoxynucleotide at 3 ' of PCR product that the Taq polysaccharase has the terminal enzyme (DNA) of the template of not relying on, and preference is added deoxyadenylic acid (the A) (Clark in four kinds of deoxynucleotides, J.M., 1988.Novelnon-templated nucleotide addition reactions catalyzed prokaryotic andeucaryotic DNA polymerase.Nucleic Acids Res.16,9677-9686; Cha, J., Bishai, W., Chandrasegaran, S., 1993.New vectors for direct cloning of PCR products.Gene 136,369-370; Schutte, B.C., Ranade, K., Pruessner, J., Dracopoli, N., 1997.Optimized conditions for cloning PCR products into an XcmI T-vector.BioTechniques 22 40-42), makes 3 ' end of the PCR product more than 50% have single deoxyadenylic acid, promptly 3 ' hold A tail (Ichihara, Y., Kurosawa, Y., 1993.Construction of new Tvectors for direct cloning of PCR products.Gene 130,153-154).
At present, the preparation method of T carrier has 3 kinds.First method is to utilize the restriction endonuclease that produces flat end that the cyclic plasmid enzyme is cut into the wire plasmid, utilize terminal enzyme (DNA) single pair of dT acid (ddTTP) to be added to 3 ' end (Holton of wire carrier then, T.A., Graham, M.W., 1991.A simple and efficientmethod for direct cloning of PCR products using ddT-tailed vectors.NucleicAcids Res.19,1156).Second method is the 3 ' end (Marchuk that the terminal enzyme (DNA) activity that does not rely on template of utilizing the Taq enzyme is added single dT acid (dTTP) in the wire carrier, D., Drumm, M., Saulino, A., Collins, F.S., 1991.Construction of T-vectors, a rapid andgeneral system for direct cloning of unmodified PCR products.Nucleic AcidsRes.19,1154).The third method is to introduce specific restriction enzyme site in the multiple clone site of plasmid vector, produces 3 ' end with corresponding endonuclease digestion and has the outstanding linear T carrier of single T.Preceding two kinds of methods exist tailing efficient sequences lower and linear plasmid its two ends in the tailing process problem (Shuman such as to be partially removed sometimes in preparation T carrier process, S., 1994.Novel approach to molecular cloning andpolynucleotide synthesis using vaccinia DNA topoisomerase.J.Biol.Chem.265,32678-32684).Compare with preceding two kinds of methods, the third method is faster, more efficient and more stable.In theory, the restriction endonuclease that can be used for preparing the T carrier comprises: XcmI (Jo, C., Jo, S.A., 2001.A simple methodto construct T vectors using Xcm I cassettes amplified by nonspecific PCR.Plasmid 45,37-40; Arashi, N., Miwa, M., Shibata, H., 1999.XcmIsite-containing vector for direct cloning and in vitro transcription for PCRproduct.Mol.Biotechnol.12,281-283), AhdI/Eam1105I/EclHKI/AspEI/NruGI/BspOVI (Jeung, J.U., Cho, S.K., Shim, K.S., Ok, S.H., Lim, D.S., Shin, J.S., 2002.Construction of two pGEM-7Zf (+) phagemid T-tail vectors using AhdI-restriction endonuclease sites for direct cloning of PCR products.Plasmid48,160-163; Ichihara, Y., Kurosawa, Y., 1993.Construction of new T vectorsfor direct cloning of PCR products.Gene 130,153-154), BfiI/BmrI, HphI/AsuHPI (Mead, D.A., Pey, N.K., Herrnstadt, C., Marcil, R.A., Smith, L.M., 1991.A universal method for the direct cloning of PCR amplified nucleic acid.Bio/Technology 9,657-663), MboII/NcuI, BfuI/BciVI, HpyAV/Hin4II.Wherein XcmI and AhdI and isoschizomers thereof are used widely in preparation T carrier.Other restriction endonuclease or because too expensive, or because too many recognition site is arranged on common cloning vector, thereby the application in preparation T carrier is restricted.In the common cloning vector that contains the Amp resistance, for example pUC18, pBlueScript SK carrier etc., do not have the XcmI restriction enzyme site, but the restriction enzyme site that in the Amp resistant gene, contains an AhdI and isoschizomers thereof, thereby more more convenient in the multiple clone site introducing XcmI site of these carriers, Here it is, and why more people adopt XcmI to prepare T carrier (american documentation literature US005487993A; Chinese patent literature CN1142279C, CN1344795A and CN1362521A).If introduce the restriction enzyme site of AhdI and isoschizomers thereof, then must be by corresponding restriction enzyme site in the reticent Amp resistant gene of the method for rite-directed mutagenesis.However, utilize AhdI and isoschizomers thereof to prepare the T carrier and more have superiority, show following several aspect compared with XcmI.First, AhdI has 5 kinds of isoschizomerss, 4 kinds of isoschizomers commercializations wherein, thereby add that AhdI has 5 kinds of restriction endonucleases can supply to select for use, and XcmI does not have isoschizomers (Roberts R.J., T.Vincze, J.Posfai, and D.Macelis.2003.REBASE:restriction enzymes andmethyltransferases.Nucleic Acids Res.31:418-420).Second, the performance of AhdI restriction endonuclease is better than XcmI (Jeung, J.U., Cho, S.K., Shim, K.S., Ok, S.H., Lim, D.S., Shin, J.S., 2002.Construct ion of two pGEM-7Zf (+) phagemid T-tail vectors using AhdI-restriction endonuclease sites for direct cloning of PCR products.Plasmid48,160-163), and the sale price of market of AhdI is far below XcmI (seeing " NEB products catalogue and technical information ", 2003-2004 year).The 3rd, the sequence of AhdI and isoschizomers thereof identification 11bp, and the sequence of XcmI identification 15bp, thereby introduce (for example in the PCR primer, introducing) AhdI and the isoschizomers recognition sequence easier.
No matter be to use XcmI also to be to use AhdI and isoschizomers thereof to make up the T carrier and all have a potential problem: partially digested pre-T carrier is mingled in the too high (Mead of the background that can cause non-recombinant conversion in the T carrier, D.A., Pey, N.K., Herrnstadt, C., Marcil, R.A., Smith, L.M., 1991.A universal methodfor the direct cloning of PCR amplified nucleic acid.Bio/Technology 9,657-663; Harrison, J., Molly, P.L., Clark, S.J., 1994.Direct cloning ofpolymerase chain reaction products in an XcmI T-vector.Anal.Biochem.216,235-236).At present, address this problem effective means and be between two XcmI of pre-T carrier or two AhdI restriction enzyme sites and introduce sufficiently long spacer DNA, behind agarose gel electrophoresis, the plasmid of complete degestion and partially digested plasmid are separated (Testori, A., Sollitti, P., 1996.Cloning unmodified PCRproducts using engineered XcmI restriction sites in a portable cassette.Methods Mol.Biol.67,89-100; Jo, C., Jo, S.A., 2001.A simple method toconstruct T vectors using Xcm I cassettes amplified by nonspecific PCR.Plasmid45,37-40; Jeung, J.U., Cho, S.K., Shim, K.S., Ok, S.H., Lim, D.S., Shin, J.S., 2002.Construction of two pGEM-7Zf (+) phagemid T-tail vectors using AhdI-restriction endonuclease sites for direct cloning of PCR products.Plasmid48,160-163).Yet, introducing a new problem of bringing behind the spacer DNA is: because ring-like plasmid moves soon compared with the suitable linear plasmid of molecular weight in agarose gel electrophoresis, thereby, not digested ring-like plasmid (pre-T carrier, have spacer DNA) often mix with the T carrier (not having spacer DNA) of molecular weight less than self, finally cause the background of non-recombinant conversion too high.
PBlueScript II SK (+/-) carrier (GenBank Accession No.X52330) is to be derived from and the phagemid carrier (phagemid or phasmid) that comes by the pUC carrier, except containing an Amp resistant gene and a lacZ gene as the selection markers, the promotor that has T3 and T7 phage in the both sides of multiple clone site has the replication orgin (unique difference of pBlueScript II SK (+) and pBlueScript II SK (-) is the oppositely opposite of both f1) of a single stranded phage f1 simultaneously.
CcdB gene (GenBank Accession No.AP001918) is positioned on the F plasmid, and it and ccdA gene constitute ccd (the control of cell death) site of F plasmid together.The ccd site reaches the effect of stablizing the F plasmid by killing the Bacillus coli cells that does not contain the F plasmid.CcdB albumen disturbs colibacillary dna gyrase, thereby suppress most of coli strains (DH5 α for example, JM109, DH10B, growth TOP10) (Bernard, P., and Couturier, M., 1992.Cell Killing by the F Plasmid CcdB Protein InvolvesPoisoning of DNA-Topoisomerase II Complexes.J.Mol.Biol.226,735-745).But place sudden change has taken place in the A subunit gene of gyrase in the intestinal bacteria DB3.1 bacterial strain, gyrase after the sudden change can be resisted the proteic toxic effect of CcdB, thereby the plasmid that contains the ccdB gene can be bred (Miki in the DB3.1 bacterial strain, T., Park, J.A., Nagao, K., Murayama, N., and Horiuchi, T., 1992.Control of Segregation of Chromosomal DNA by Sex Factor F in Escherichia coli.Mutants of DNA Gyrase Subunit A Suppress letD (ccdB) Product Growth Inhibition.J.Mol.Biol.225,39-52).
Summary of the invention
The purpose of this invention is to provide T carrier with higher TA cloning efficiency.
T carrier provided by the present invention comprises the Amp of pBlueScript II SK (-)
r(Amp resistant gene) gene order, the ColEI ori of pBlueScript II SK (-) (replication origin of plasmid ColEI) sequence, the f1 ori of pBlueScript II SK (-) (replication origin of single stranded phage f1) sequence, the lacZ gene order of pBlueScript IISK (-), the T3 bacteriophage promoter sequences of pBlueScript II SK (-), the T7 bacteriophage promoter sequences of pBlueScriptII SK (-) and each the multiple clone site sequence that lays respectively at two ends, wherein, described Amp
rAhdI restriction enzyme site in the gene order is by silence, and described two multiple clone site all have 3 ' outstanding T end.
The sequence of described 3 ' outstanding T end can be:
5′GGACNNT3′
3 ' CCTGNN 5 ', wherein N is A or T or C or G.
Described each multiple clone site sequence that is arranged in two ends can by pBlueScript II SK (-) one to 11 restriction enzyme site sequence form.
Wherein, the AhdI restriction enzyme site of the Amp resistant gene among the pBlueScript II SK (-) can pass through the mutation method silence, as the method by rite-directed mutagenesis, will sport C from 5 of Amp resistant gene ' end the 783rd bit base G.
Described T carrier is preferably pSK01-T (its physical map as shown in Figure 2) or pSK02-T (its physical map as shown in Figure 3) or pSK03-T (its physical map as shown in Figure 4) or pSK04-T (its physical map as shown in Figure 5).
Second purpose of the present invention provides a kind of method for preparing above-mentioned T carrier.
The method of the above-mentioned T carrier of preparation provided by the present invention may further comprise the steps:
1) with the AhdI restriction enzyme site silence of the Amp resistant gene among the pBlueScript II SK (-);
The multiple clone site of the carrier that 2) obtains in step 1) is introduced the AhdI box, obtains pre-T carrier; Described AhdI box by the ccdB gene order, closely be connected in each AhdI restriction enzyme site sequence of described ccdB gene order both sides and the restriction enzyme site sequence that closely is connected in the multiple clone site of pBlueScript II SK (-) of described each AhdI restriction enzyme site sequence is formed;
3) cut step 2 with the isoschizomers enzyme of AhdI or AhdI) in pre-T carrier, obtain the T carrier.
Wherein, the AhdI restriction enzyme site of the Amp resistant gene among the pBlueScript II SK (-) can pass through the mutation method silence, as the method by rite-directed mutagenesis, will sport C from 5 of Amp resistant gene ' end the 783rd bit base G.
Step 2) in, the AhdI box can be introduced between any two restriction enzyme sites of described multiple clone site, is preferably introducing described AhdI box between SalI restriction enzyme site and the XbaI enzyme cutting site or between KpnI restriction enzyme site and the SacI restriction enzyme site or between EcoRI restriction enzyme site and the EcoRI restriction enzyme site or between EagI restriction enzyme site and the EagI restriction enzyme site.
Described AhdI box is preferably the nucleotide sequence that has shown in sequence in the sequence table 1, sequence 2, sequence 3 or sequence 4.
Sequence 1 in the sequence table is by 343 based compositions; Sequence 2 in the sequence table is by 343 based compositions; Sequence 3 in the sequence table is by 343 based compositions; Sequence 4 in the sequence table is by 373 based compositions.
Described pre-T carrier is preferably pSK01 or pSK02 or pSK03 or pSK04; Described T carrier is preferably pSK01-T (its physical map as shown in Figure 2) or pSK02-T (its physical map as shown in Figure 3) or pSK03-T (its physical map as shown in Figure 4) or pSK04-T (its physical map as shown in Figure 5).
The isoschizomers of described AhdI comprises Eam1105I/EclHKI/AspEI/NruGI/BspOVI.
The AhdI box that the present invention prepares in the method for T carrier adopts the ccdB gene as spacer DNA, makes spacer DNA have at interval two AhdI restriction enzyme sites simultaneously and as the negative dual function of selecting mark.Can in the DB3.1 bacterial strain, breed as the pre-T carrier of spacer DNA with the ccdB gene, when the linked system that T carrier and PCR product etc. are formed transforms Bacillus coli communis bacterial strain (DH5 α for example, JM109, DH10B, TOP10) time, mix pre-T carrier in the T carrier (comprising ring-like plasmid that enzyme is not cut and the partially digested ring-like plasmid of linear plasmid) and can kill Bacillus coli cells through being formed by connecting.Like this, the too high problem of the sub-background of non-recombinant conversion that is caused by pre-T carrier in the TA clone process is solved.In addition, the T tail of sub-fraction T carrier (for example exonuclease activity that AhdI and isoschizomers and ligase enzyme etc. are remaining, multigelation etc.) for various reasons can be removed, and the T carrier of removing the T tail is another source of forming the sub-background of non-recombinant conversion through self connecting the transformant that produces.Method of the present invention makes non-recombinant conversion in above-mentioned source have complete lacZ reading frame by accurate design AhdI box, thereby can remove this non-recombinant conversion through blue hickie screening.
The method of the T of preparation carrier of the present invention can reduce miscellaneous in the T the carrier not ring-like plasmid cut of enzyme and partially digested linear plasmid to greatest extent.
The pSKxx series pre-T carrier (comprising pSK01, pSK02, pSK03 and pSK04) of the present invention's structure and the pSKxx-T series T carrier (comprising pSK01-T, pSK02-T, pSK03-T and pSK04-T) that is come by these pre-T carriers preparations are based on pBlueScript II SK (-) structure and form.These carriers have the characteristics of following several aspects:
1, all characteristics that has pBlueScript II SK (-) carrier.Except containing an Amp resistant gene and a lacZ gene as the selection markers, there is the promotor of T3 and T7 phage in the both sides of multiple clone site, have the replication orgin of a single stranded phage f1 simultaneously.
2, utilize rite-directed mutagenesis the method silence AhdI restriction enzyme site of Amp resistant gene in pBlueScript II SK (-) carrier.The carrier called after pSK Δ Ahd of reticent AhdI restriction enzyme site.The base (base in the frame) that the rite-directed mutagenesis front and back take place in the Amp resistant gene is as follows:
Sequence before the sudden change:
Sequence after the sudden change:
3, pSKxx series pre-T carrier is to introduce AhdI box structure to form in the multiple clone site of pSK Δ Ahd.The core sequence of AhdI box following (dash area shows the AhdI restriction enzyme site, and partly representing ccdB gene order, N in the frame is A or T or C or G, the concrete site of " ^ " expression enzyme cutting):
4, the ccdB gene in the AhdI box has spacer DNA and the negative dual function of selecting mark.CcdB is meant that as spacer DNA the ccdB gene order is spaced apart with two AhdI restriction enzyme sites, and the ccdB gene will kill Bacillus coli cells after being transformed into the Bacillus coli communis strain cell as the negative plasmid that selects marker gene to be meant to contain the ccdB gene.CcdB gene in the AhdI box can have three kinds of forms: first kind of lacZ reading frame fusion that form is ccdB gene and its front, and under the lacZ promoters driven, express to produce and merge CcdB albumen; The front that second kind of form is the ccdB gene has ribosome bind site (RBS) sequence, expresses to produce CcdB albumen under the lacZ promoters driven; The third form is that the front of ccdB gene has self promotor and RBS sequence, expresses producing CcdB albumen under the double drive of lacZ promotor and himself promotor.
5, use AhdI restriction endonuclease or its isoschizomers (Eam1105I/EclHKI/AspEI/NruG/BspOVI) enzyme to cut pSKxx series pre-T carrier, enzyme is cut system and is separated through agarose gel electrophoresis, and the big fragment of cutting the glue recovery promptly is corresponding T carrier.The difference of 4 kinds of T carriers is the kind and the different amts of restriction enzyme site in the multiple clone site.Wherein, pSK02-T has minimum restriction enzyme site, can reduce the influence to in-vitro transcription of high GC content and palindrome, so pSK02-T is particularly suitable for carrying out in-vitro transcription to inserting fragment.PSK03-T has kept whole restriction enzyme sites of pBlueScript IISK (-) carrier, therefore can select more restriction endonuclease to discharge from the T carrier and insert fragment.In addition, owing to additionally introduced an EcoR I restriction enzyme site, therefore can discharge from the T carrier and insert fragment with EcoR I single endonuclease digestion.How paired restriction enzyme site has been introduced in the TA cloning site both sides of pSK04-T carrier, therefore can identify positive colony or discharge with more restriction endonuclease single endonuclease digestion and insert fragment, NotI restriction enzyme site wherein belongs to rare restriction enzyme site, and it is very low to insert the probability that contains this restriction enzyme site in the fragment.
6, the sub-fraction in the serial T carrier of pSKxx-T (comprising pSK01-T, pSK02-T, pSK03-T and pSK04-T) of preparation (for example exonuclease activity that AhdI and isoschizomers and ligase enzyme etc. are remaining, multigelation etc.) when its T tail is removed for various reasons, these plasmids that lose the T tail can form complete lacZ reading frame after self connects, thereby can get rid of these non-recombinant conversion by blue hickie method for screening.
When carrying out the TA clone, the T carrier that adopts method of the present invention to prepare, therefore improved the quality and the stability of T carrier greatly owing to thoroughly solved the too high problem of the sub-background of non-recombinant conversion.The T carrier great majority of selling on the market are based on pUC18 or pUC19 makes up, and the pSKxx-T series T carrier of the present invention's preparation is based on pBlueScript II SK (-) structure and forms, and has more good quality production characteristic.Experimental results show that T carrier of the present invention clones the TA cloning efficiency of PCR product of 1.8kb and 0.68kb respectively more than 95%.T carrier of the present invention and preparation method thereof will play an important role in the genetically engineered field.
Description of drawings
Figure 1A is the structural representation of AhdI box among the pre-T carrier pSK01
Figure 1B is the structural representation of AhdI box among the pre-T carrier pSK02
Fig. 1 C is the structural representation of AhdI box among the pre-T carrier pSK03
Fig. 1 D is the structural representation of AhdI box among the pre-T carrier pSK04
Fig. 2 is the physical map of pSK01-T
Fig. 3 is the physical map of pSK02-T
Fig. 4 is the physical map of pSK03-T
Fig. 5 is the physical map of pSK04-T
Embodiment
The structure of embodiment 1, pSK Δ Ahd
Utilize the AhdI restriction enzyme site of Amp resistant gene in reticent pBlueScript SK (-) carrier of method of rite-directed mutagenesis, obtain pSK Δ Ahd, its concrete construction process is as follows: the base of introducing sudden change in the PCR primer, with pBluescript II SK (-) carrier is template, carries out pcr amplification with the Pfu archaeal dna polymerase.Wherein, the pcr amplification primer is (add the mutational site (in original series be G) of C for introducing of frame, dash area is the AhdI restriction enzyme site after sudden change destroys):
AmpF:5’-CTACGATACGGGAGGGCTTACCATCTGG-3’;
The reaction system of pcr amplification is: contain 5U Pfu in the 50 μ L reaction systems, and 0.2mmol/L dNTPs, 1 * Pfu buffer, each 10 μ mol/L of primer are about template 5ng; The cycling program of pcr amplification is: 94 ℃ of pre-sex change 5min, (94 ℃, 30S; 60 ℃, 30S; 72 ℃, 5min) * 30, the 72 ℃ last 5min that extends.Behind 1% agarose gel electrophoresis, cut glue and reclaim pcr amplification product.Afterwards, set up following ligation: contain 3U ligase enzyme (Promega) in the 10 μ L linked systems, 1 * connection Buffer, about 50ng PCR product.4 ℃ connect 16 hours.After will connecting product transformed into escherichia coli (DH10B), behind blue hickie and Amp resistance screening, obtain positive colony, at random 6 positive colonies of picking, order-checking one by one, obtain AhdI restriction enzyme site ruined pBluescript II SK (-) carrier, called after pSK Δ Ahd.Wherein, the base (base in the frame) before and after the generation rite-directed mutagenesis is as follows in the Amp resistant gene:
Sequence before the sudden change:
Sequence after the sudden change:
Sequencing primer is: Amp18:5 '-AATAGACTGGATGGAGGC-3 '.
Embodiment 2, in the multiple clone site of pSK Δ Ahd, introduce the AhdI box and make up pre-T carrier
With plasmid pENTR1A (available from Invitrogen company) is template, carries out pcr amplification with CcdB01F and CcdB01R primer.The reaction system of pcr amplification is: contain 5U Pfu in the 50 μ L reaction systems, and 0.2mmol/LdNTPs, 1 * Pfu buffer, each 10 μ mol/L of primer are about template 5ng; The cycling program of pcr amplification is: 94 ℃ of pre-sex change 5min, (94 ℃, 30S; 60 ℃, 30S; 72 ℃, 1.5min) * 30, the 72 ℃ last 5min that extends.The PCR product is cut glue and is reclaimed behind 1% agarose gel electrophoresis, the PCR product and the pSK Δ Ahd plasmid that reclaim are used SalI and XbaI double digestion respectively, and enzyme is cut product and cut the glue recovery behind 1% agarose gel electrophoresis.PSK Δ Ahd carrier after PCR product after enzyme cut and enzyme are cut is set up following ligation system: contain 3U ligase enzyme (Promega) in the 10 μ L linked systems, 1 * connect Buffer, about 50ng plasmid, about 50ng PCR product.4 ℃ connect more than 16 hours.Connect product and transform DB3.1 bacterial strain (Invitrogen) according to ordinary method.Obtain positive bacterium colony through the Amp resistance screening, positive bacterium colony is identified through order-checking and is obtained pre-T carrier pSK01.
The building process of pSK02 is that CcdB02F and CcdB02R and resulting pcr amplification product and pSK Δ Ahd use respectively SacI and the KpnI double digestion except that used pcr amplification primer, other step and pSK01 with.
The structure of the building process of pSK03 and pSK01 and pSK02 is similar substantially, different is to carry out pcr amplification with CcdB03F and CcdB03R primer, pcr amplification product and pSK Δ Ahd plasmid are cut with the EcoRI enzyme respectively, and the pSK Δ Ahd plasmid after enzyme is cut is being removed 5 '-phosphoric acid to prevent recirculation with handling with alkaline phosphatase before PCR product after enzyme is cut is connected.Connect product and transform the DB3.1 intestinal bacteria, carry out colony PCR amplification, identify the positive colony that inserts (consistent) with forward, obtain pSK03 with lacZ reading frame direction with M13-47 and ccdBR primer according to ordinary method.
The building process of pSK04 was divided into for two steps.The first step is a template with the pENT-NL plasmid (http://deepgreen.stanford.edu/cell imaging site/html/vectors.html) that contains the EGFP gene, is that primer carries out pcr amplification with EGFPF and EGFPR.The reaction system of pcr amplification is: contain 5U Pfu in the 50 μ L reaction systems, and 0.2mmol/L dNTPs, 1 * Pfu buffer, each 10 μ mol/L of primer are about template 5ng; The cycling program of pcr amplification is: 94 ℃ of pre-sex change 5min, (94 ℃, 30S; 60 ℃, 30S; 72 ℃, 2min) * 30, the 72 ℃ last 5min that extends.The PCR product is cut glue and is reclaimed behind 1% agarose gel electrophoresis, the PCR product and the pSK Δ Ahd that reclaim are used SacI and KpnI double digestion respectively, PCR product after enzyme is cut and pSK Δ Ahd set up following ligation system: contain 3U ligase enzyme (Promega) in the 10 μ L linked systems, 1 * connection Buffer, about 50ng plasmid, 50ng PCR product.4 ℃ connect 16 hours.Connect product according to the ordinary method transformed into escherichia coli, obtain positive bacterium colony through the Amp resistance screening, positive bacterium colony obtains intermediate carrier pSKEGFP after order-checking is identified.Second step was a template with plasmid pENTR1A, carried out pcr amplification with CcdB04F and CcdB04R primer.The reaction system of pcr amplification is: contain 5U Pfu in the 50 μ L reaction systems, and 0.2mmol/L dNTPs, 1 * Pfu buffer, each 10 μ mol/L of primer are about template 5ng; The cycling program of pcr amplification is: 94 ℃ of pre-sex change 5min, (94 ℃, 30S; 60 ℃, 30S; 72 ℃, 1.5min) * 30, the 72 ℃ last 5min that extends.The PCR product is cut glue and is reclaimed behind 1% agarose gel electrophoresis, the PCR product and the pSKEGFP that reclaim are cut with the NotI enzyme respectively, pSKEGFP after enzyme is cut sets up following ligation system with the PCR product that alkaline phosphatase is handled after cut with enzyme the back: contain 3U ligase enzyme (Promega) in the 10 μ L linked systems, 1 * connection Buffer, about 50ng plasmid, 50ng PCR product.4 ℃ connect 16 hours.Connect product and transform DB3.1 bacterial strain (Invitrogen), carry out bacterium colony PCR, identify the positive colony that inserts (consistent) with forward, obtain pSK04 with lacZ reading frame direction with M13-47 and ccdBR primer according to ordinary method.
Be used for making up the primer sequence following (sequence of left side square frame is a restriction enzyme site, and the sequence in the middle shade is the AhdI restriction enzyme site, and the sequence in the square frame of the right is the sequence from ccdB or EGFP gene) of above-mentioned pre-T carrier (pSK01,02,03 and 04):
CcdB01F:
CcdB02F:
CcdB03F:
CcdB04F:
CcdB04R:
M13-47:5’-CGCCAGGGTTTTCCCAGTCACGAC-3’
CcdBR:5’-TCAGCCACTTCTTCCCCGATAACG-3’
The structure of the AhdI box among pre-T carrier pSK01, pSK02, pSK03 and the pSK04 is shown in Figure 1A-Fig. 1 D, among Figure 1A-Fig. 1 D, sequence in the square frame of both sides is a restriction enzyme site, sequence in the shade is respectively two AhdI restriction enzyme sites, part in the middle square frame is represented the ccdB gene order, the concrete site of " ^ " expression enzyme cutting.Sequence among Figure 1A in the square frame of both sides is respectively SalI and XbaI enzyme cutting site, sequence among Figure 1B in the square frame of both sides is respectively SacI and KpnI restriction enzyme site, sequence among Fig. 1 C in the square frame of both sides is the EcoRI restriction enzyme site, sequence among Fig. 1 D in the left frame comprises the SacI-EcoRI-SacII-NotI-EagI restriction enzyme site, and the sequence in the right-hand frame comprises the EagI-NotI-SacII-EcoRI-KpnI restriction enzyme site.First restriction enzyme site among restriction enzyme site among Figure 1A-1C in the square frame of both sides and Fig. 1 D in the square frame of the left side and last restriction enzyme site in the square frame of the right correspond respectively to the restriction enzyme site on pBlueScript SK (-) plasmid.
The preparation and the TA cloning efficiency of embodiment 3, pSKxx-T series T carrier are analyzed
1, preparation T carrier
With AhdI respectively enzyme cut pre-T carrier pSK01,02,03 and 04, the endonuclease reaction system is as follows: 20 μ L enzymes are cut and are contained 3U AhdI restriction endonuclease (available from NEB company) in the system, 1 * NEBuffer4, about 1 μ g plasmid.After 37 ℃ of enzymes are cut 3 hours, behind 1% agarose gel electrophoresis, cut glue respectively and reclaim big fragment.The big fragment of cutting glue recovery purifying promptly is corresponding T carrier.The physical map of pSK01-T, pSK02-T, pSK03-T and pSK04-T is respectively as Fig. 2, Fig. 3, Fig. 4 and shown in Figure 5.
2, test TA cloning efficiency
With the Taq archaeal dna polymerase is primer PCR amplification Arabidopis thaliana NCED3 (1.8kb with NCEDF and NCEDR respectively, GenBank Accession No.AT3G14440) with DREBF and DREBR is primer PCR amplification DREB1A (680bp, GenBank Accession No.At4g25480) gene fragment.Primer sequence is as follows:
NCEDF?5’-AACGGATCCATGGCTTCTTTCACGGCAACGGC-3’
NCEDR?5’-AACGAGCTCTCACACGACCTGCTTCGCCAAATC-3’
DREBF?5’-AAGGATCCTTCTGATCAATGAACTCATTTTCTG-3’
DREBR?5’-AACACGTGGTTTTAATAACTCCATAACGATACG-3’
Pcr amplification product is cut glue and is reclaimed behind 1% agarose gel electrophoresis.Set up 8 ligation systems, reaction system is as follows: contain 3U ligase enzyme (Promega) in the 10 μ L linked systems, 1 * connect Buffer, the T carrier of about 50ng and the NCED3 of about 92ng or the DREB1A of 35ng, 4 ℃ connect more than 16 hours.Connect product according to ordinary method transformed into escherichia coli DH10B, and carry out blue hickie screening.Each linked system 30 hickies of random choose is respectively carried out bacterium colony PCR evaluation, calculates the shared per-cent of positive colony.The result shows, pSK01,02,03 and 04 and the TA cloning efficiency of the DREB1A ligation of setting up be 100% (30/30); PSK01,02,03 and 04 and the TA cloning efficiency of the NCED3 ligation of setting up be respectively 100% (30/30), 100% (30/30), 96% (29/30) and 96% (29/30).Locus coeruleus quantity behind 8 linked system transformed into escherichia coli all is lower than 5% with the ratio of total colony number.These results show that the T carrier of the present invention's preparation has very high TA cloning efficiency.
Sequence table
<160>4
<210>1
<211>343
<212>DNA
<213〉artificial sequence
<220>
<223>
<400>1
tctagaggac?tttaggtcga?tgcagtttaa?ggtttacacc?tataaaagag?agagccgtta 60
tcgtctgttt?gtggatgtac?agagtgatat?tattgacacg?cccgggcgac?ggatagtgat 120
ccccctggcc?agtgcacgtc?tgctgtcaga?taaagtctcc?cgtgaacttt?acccggtggt 180
gcatatcggg?gatgaaagct?ggcgcatgat?gaccaccgat?atggccagtg?tgccggtctc 240
cgttatcggg?gaagaagtgg?ctgatctcag?ccaccgcgaa?aatgacatca?aaaacgccat 300
taacctgatg?ttctggggaa?tataggacca?aaagtccgtc?gac 343
<210>2
<211>343
<212>DNA
<213〉artificial sequence
<220>
<223>
<400>2
gagctcggac?tttaggtcga?tgcagtttaa?ggtttacacc?tataaaagag?agagccgtta 60
tcgtctgttt?gtggatgtac?agagtgatat?tattgacacg?cccgggcgac?ggatagtgat 120
ccccctggcc?agtgcacgtc?tgctgtcaga?taaagtctcc?cgtgaacttt?acccggtggt 180
gcatatcggg?gatgaaagct?ggcgcatgat?gaccaccgat?atggccagtg?tgccggtctc 240
cgttatcggg?gaagaagtgg?ctgatctcag?ccaccgcgaa?aatgacatca?aaaacgccat 300
taacctgatg?ttctggggaa?tataggacca?aaagtccggt?acc 343
<210>3
<211>343
<212>DNA
<213〉artificial sequence
<220>
<223>
<400>3
gaattcggac?tttaggtcga?tgcagtttaa?ggtttacacc?tataaaagag?agagccgtta 60
tcgtctgttt?gtggatgtac?agagtgatat?tattgacacg?cccgggcgac?ggatagtgat 120
ccccctggcc?agtgcacgtc?tgctgtcaga?taaagtctcc?cgtgaacttt?acccggtggt 180
gcatatcggg?gatgaaagct?ggcgcatgat?gaccaccgat?atggccagtg?tgccggtctc 240
cgttatcggg?gaagaagtgg?ctgatctcag?ccaccgcgaa?aatgacatca?aaaacgccat 300
taacctgatg?ttctggggaa?tataggacca?aaagtccgaa?ttc 343
<210>4
<211>373
<212>DNA
<213〉artificial sequence
<220>
<223>
<400>4
gagctcgaat?tcccgcggcc?gcgactttag?gtcgatgcag?tttaaggttt?acacctataa 60
aagagagagc?cgttatcgtc?tgtttgtgga?tgtacagagt?gatattattg?acacgcccgg 120
gcgacggata?gtgatccccc?tggccagtgc?acgtctgctg?tcagataaag?tctcccgtga 180
actttacccg?gtggtgcata?tcggggatga?aagctggcgc?atgatgacca?ccgatatggc 240
cagtgtgccg?gtctccgtta?tcggggaaga?agtggctgat?ctcagccacc?gcgaaaatga 300
catcaaaaac?gccattaacc?tgatgttctg?gggaatatag?gaccaaaagt?cgcggccgcg 360
ggaattcggt?acc 373
Claims (10)
1, a kind of T carrier comprises the Amp of pBlueScript II SK (-)
rGene order, the ColEI ori sequence of pBlueScript II SK (-), the f1 ori sequence of pBlueScript II SK (-), the lacZ gene order of pBlueScript II SK (-), the T3 bacteriophage promoter sequences of pBlueScript II SK (-), the T7 bacteriophage promoter sequences of pBlueScript IISK (-) and each the multiple clone site sequence that lays respectively at two ends is characterized in that: described Amp
rAhdI restriction enzyme site in the gene order is by silence, and described two multiple clone site all have 3 ' outstanding T end.
2, T carrier according to claim 1 is characterized in that: the sequence of described 3 ' outstanding T end is:
5′GGACNNT3′
3 ' CCTGNN 5 ', wherein N is A or T or C or G.
3, T carrier according to claim 1 and 2 is characterized in that: described each multiple clone site sequence that is arranged in two ends by pBlueScript II SK (-) one to 11 restriction enzyme site sequence form.
4, T carrier according to claim 3 is characterized in that: described T carrier is pSK01-T or pSK02-T or pSK03-T or pSK04-T.
5, a kind of method for preparing the described T carrier of claim 1 may further comprise the steps:
1) with the AhdI restriction enzyme site silence of the Amp resistant gene among the pBlueScript II SK (-);
The multiple clone site of the carrier that 2) obtains in step 1) is introduced the AhdI box, obtains pre-T carrier; Described AhdI box by the ccdB gene order, closely be connected in each AhdI restriction enzyme site sequence of described ccdB gene order both sides and the restriction enzyme site sequence that closely is connected in the multiple clone site of pBlueScript II SK (-) of described each AhdI restriction enzyme site sequence is formed;
3) cut step 2 with the isoschizomers enzyme of AhdI or AhdI) in pre-T carrier, obtain the T carrier.
6, method according to claim 5, it is characterized in that: step 2) in, described AhdI box introduced between the SalI of described multiple clone site restriction enzyme site and the XbaI enzyme cutting site or between KpnI restriction enzyme site and the SacI restriction enzyme site or between EcoRI restriction enzyme site and the EcoRI restriction enzyme site or between EagI restriction enzyme site and the EagI restriction enzyme site.
7, according to claim 5 or 6 described methods, it is characterized in that: described AhdI box has the nucleotide sequence of sequence 1 in the sequence table, sequence 2, sequence 3 or sequence 4.
8, method according to claim 7 is characterized in that: described pre-T carrier is pSK01 or pSK02 or pSK03 or pSK04.
9, method according to claim 8 is characterized in that: described T carrier is pSK01-T or pSK02-T or pSK03-T or pSK04-T.
10, the pre-T carrier pSK01 of the described T carrier of claim 1 or pSK02 or pSK03 or pSK04.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100479050A CN100494384C (en) | 2004-06-10 | 2004-06-10 | T vector and its construction method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100479050A CN100494384C (en) | 2004-06-10 | 2004-06-10 | T vector and its construction method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1590550A true CN1590550A (en) | 2005-03-09 |
CN100494384C CN100494384C (en) | 2009-06-03 |
Family
ID=34602037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100479050A Expired - Fee Related CN100494384C (en) | 2004-06-10 | 2004-06-10 | T vector and its construction method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100494384C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100383248C (en) * | 2005-12-15 | 2008-04-23 | 南京大学 | Preparation method of T vector for T-A cloning |
CN101177689B (en) * | 2006-11-09 | 2011-01-26 | 天津医科大学 | Method for high-effective construction of T-carrier based on polymerase chain reaction |
CN108588102A (en) * | 2017-12-29 | 2018-09-28 | 苏州金唯智生物科技有限公司 | Carrier T and the application of a kind of pre-T carrier and its composition |
CN111235172A (en) * | 2020-02-24 | 2020-06-05 | 扬州大学 | Prokaryotic promoter report system based on lacZ gene and pUC replicon, and construction method and application thereof |
-
2004
- 2004-06-10 CN CNB2004100479050A patent/CN100494384C/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100383248C (en) * | 2005-12-15 | 2008-04-23 | 南京大学 | Preparation method of T vector for T-A cloning |
CN101177689B (en) * | 2006-11-09 | 2011-01-26 | 天津医科大学 | Method for high-effective construction of T-carrier based on polymerase chain reaction |
CN108588102A (en) * | 2017-12-29 | 2018-09-28 | 苏州金唯智生物科技有限公司 | Carrier T and the application of a kind of pre-T carrier and its composition |
CN108588102B (en) * | 2017-12-29 | 2021-10-08 | 苏州金唯智生物科技有限公司 | Pre-T vector, T vector composed of pre-T vector and application of pre-T vector |
CN111235172A (en) * | 2020-02-24 | 2020-06-05 | 扬州大学 | Prokaryotic promoter report system based on lacZ gene and pUC replicon, and construction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100494384C (en) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1263860C (en) | Construction method of multigene carrier and its application | |
EP1692290B1 (en) | Dna cloning vector plasmids and methods for their use | |
WO2019062522A1 (en) | Sgrna, engineered cas9 protein, and kit | |
CN1309717A (en) | Cell-free chimeraplasty and fukaryotic use of heteroduplex mutational vector | |
CN108546716A (en) | A kind of genome edit methods | |
CN1182247C (en) | Sequence-specific DNA recombination in ekaryotic cells | |
CN104651401A (en) | Method for knocking out two mir-505 alleles | |
KR20190133200A (en) | Novel Techniques for Direct Cloning and Large-molecule Assembly of Large Fragments of the Genome | |
CN1373803A (en) | Method and compositions for directed clonning and subclonning using homologous recombination | |
CN1590549A (en) | Method of constructing T carrier | |
EP1974037B1 (en) | Linear vectors, host cells and cloning methods | |
WO2023092731A1 (en) | Mad7-nls fusion protein, and nucleic acid construct for site-directed editing of plant genome and application thereof | |
Hou et al. | Assembly of long DNA sequences using a new synthetic Escherichia coli-yeast shuttle vector | |
CN1590550A (en) | T carrier and its construction method | |
CN112553238A (en) | CRISPR/Cas9 vector applicable to coniothyrium minitans FS482 as well as construction method and application thereof | |
CN111004813A (en) | Super-large plasmid construction kit, super-large plasmid construction method and application thereof | |
CN111850050B (en) | Gene editing tool, preparation method thereof and multi-round gene editing method | |
CN100336906C (en) | Lipase gene sequence and its application in yeast | |
CN114540356A (en) | Rhodosporidium toruloides promoter and application thereof | |
CN1802436A (en) | Plasmid having a function of T-vector and expression vector, and expression of the target gene using the same | |
CN102304537A (en) | High-molecular-weight T carrier and preparation method thereof | |
CN110982834A (en) | Plasmid construction kit, plasmid construction method and application thereof | |
CN115786229B (en) | Recombination system for rhodococcus gene knockout and application thereof | |
WO2022267843A1 (en) | Library construction method based on long overhang sequence ligation | |
CN102533741B (en) | Swine pseudo attp site and use of swine pseudo attp site |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090603 Termination date: 20110610 |